Final answer:
Patients with chemotherapeutic thrombocytopenia should avoid drugs that further reduce platelets or impair function, including cisplatin, daunorubicin, doxorubicin, and etoposide, due to the risk of exacerbating thrombocytopenia and increasing bleeding risks.
Step-by-step explanation:
Patients with chemotherapeutic thrombocytopenia are at a high risk of bleeding due to a significantly reduced platelet count. In such patients, drugs that further impair platelet function or reduce the number of platelets should be avoided. Among the medications listed, chemotherapeutic agents such as cisplatin (Platinol®), daunorubicin (Cerubidine®), doxorubicin (Adriamycin®), and etoposide (VePesid®) can cause myelosuppression and further decrease platelet count. Therefore, these drugs should NOT be given to patients suffering from thrombocytopenia induced by chemotherapy. Additionally, non-chemotherapeutic agents that affect coagulation or platelet function, such as anticoagulants like Coumadin, should be used with extreme caution, if at all, as they increase the risk of bleeding in patients with thrombocytopenia.